MDS 2022 | Parkinson’s disease modification through c-Abl inhibition

Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA, discusses Parkinson’s disease (PD) modification through Abelson tyrosine kinase (c-Abl) inhibition. The accumulation of misfolded α-synuclein is a hallmark of PD pathogenesis. Studies in animal models of PD have shown that c-Abl activation plays an essential role in the initiation and progression of α-synuclein pathology and neurodegeneration. Therefore, strategies to inhibit c-Abl hold promise as disease-modifying treatments for PD. Recently, novel c-Abl inhibitors, such as IkT-148009, demonstrated benefits in preclinical studies and are now being investigated in ongoing clinical trials. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.